|
1. Balthasar JP, A new
method for estimating clearance form pre-steady state
pharmacokinetic data. Sixth Japanese-American Conference on
Pharmacokinetics and Biopharmaceutics, 1992.
2. Balthasar JP and Fung
H-L, The production, purification and characterization of
high-affinity antibodies directed against methotrexate.
Pharmaceutical Research 11(8): S-79, 1994.
3. Balthasar JP and Fung
H-L, Utilization of anti-drug antibodies for the optimization of
intraperitoneal drug therapy: Illustration with digoxin.
FASEB Journal 8(4): A99, 1994.
4. Balthasar JP and Fung
H-L, Optimization of intraperitoneal cancer chemotherapy with
anti-drug antibodies: Pharmacokinetic rationale and experimental
results. Pharmaceutical Research 12(9):
S-3, 1995.
5. Fung H-L, Balthasar
JP and Bauer JA, Pharmacokinetics and pharmacodynamics of
organic nitrate tolerance. 3rd Jerusalem Conference on
Pharmaceutical Sciences and Clinical Pharmacology-JC , 1996.
6. Bauer JA, Balthasar
JP and Fung H-L, Rational PK/PD design of infusion regimens to
overcome nitroglycerin tolerance development. Pharmaceutical
Research 13(9): S-445, 1996.
7. Balthasar JP and
Scherrmann JM, Hybrid physiologic-compartmental model of digoxin
and anti-digoxin Fab (ADF) disposition and interaction: Accuracy
in predicting plasma concentration data from patients treated
with ADF following intentional digoxin overdoses.
Pharmaceutical Research 14(11): S-507, 1997.
8. Balthasar JP,
Alteration of vinorelbine pharmacokinetics in rats through the
infusion of a lipid emulsion. AAPS PharmSci 1(4),
1999.
9. Lobo ED and Balthasar
JP, PK/PD modeling of methotrexate toxicity in mice. American
Journal of Pharmaceutical Education 63: 71S, 1999.
10. Balthasar JP, HPLC
assay for quantification of vinorelbine in rat blood and plasma.
AAPS PharmSci 1(4), 1999.
11. Hansen RJ and
Balthasar JP, Pharmacokinetics and platelet binding of 7E3, a
murine anti-GPIIb-IIIa monoclonal antibody, in the rat. AAPS
PharmSci 1(4), 1999.
12. Hansen RJ and
Balthasar JP, Pharmacokinetics and pharmacodynamics of a murine
anti-platelet antibody, 7E3: A quantitative passive model of
immune thrombocytopenia in the rat. AAPS PharmSci 1(4),
1999.
13. Hansen RJ and
Balthasar JP, Quantification of a murine monoclonal
anti-platelet antibody, AP-3, in rat plasma using an
enzyme-linked immunosorbent assay. AAPS PharmSci 1(4),
1999.
14. Ludwig EA, Hossfeld
MS, Balthasar JP and Brass C, Impact of pharmacist-adjusted
initial antibiotic dosage. Pharmacotherapy 19(4):
540, 1999.
15. Tayab ZR and
Balthasar JP, An ELISA to quantify anti-methotrexate IgG in rat
plasma. 22nd Annual Pharmacy Student Research Conference -
Eastern States West Virginia University, 2000.
16. Lobo ED and Balthasar
JP, Prediction of agonistic and antagonistic effects of
anti-methotrexate antibodies via computer simulation. AAPS
PharmSci 2(4), 2000.
17. Lobo ED and Balthasar
JP, Application of a general time-dissociated
pharmacokinetic-pharmacodynamic model to characterize
methotrexate induced weight loss in mice. AAPS PharmSci
2(4), 2000.
18. Hansen RJ and
Balthasar JP, Effects of Pooled Human Immunoglobulin on
Anti-Platelet Antibody Production and Platelet Binding, In
Vitro. AAPS PharmSci 2(4), 2000.
19. Hansen RJ and
Balthasar JP, Pharmacokinetic /pharmacodynamic investigations
into the effects of intravenous immunoglobulin in a rat model of
immune thrombocytopenia. AAPS PharmSci 3(4), 2001.
20. Lobo ED and Balthasar
JP, Paradoxical effect of anti-methotrexate antibodies on
methotrexate toxicity: Agonistic and antagonistic effects.
AAPS PharmSci 3(4), 2001.
21. Wang EQ, Balthasar JP
and Fung HL, Pharmacodynamic modeling of in vivo nitroglycerin (NTG)
tolerance in conscious rats: Effects of dose and dosage regimen.
AAPS PharmSci 3(4), 2001.
22. Lobo ED and Balthasar
JP, Investigation of the efficacy of methotrexate chemotherapy
of mice bearing sarcoma 180 and Erhlich ascites cells, following
four equally toxic dosing protocols. AAPS PharmSci 4(4),
2002.
23. Chen J and Balthasar
JP, Determination of topotecan in mouse plasma by
high-performance liquid chromatographic assay. AAPS PharmSci
4(4), 2002.
24. Tayab ZR and
Balthasar JP, Development and validation of an enzyme-linked
immunosorbent assay for the quantification of anti-methotrexate
IgG and Fab in mouse and rat plasma. AAPS PharmSci 4(4),
2002.
25. Tayab ZR and
Balthasar JP, Application of high-dose monoclonal antibody
therapy to saturate FcRn: Investigation of the dose-dependence
of the pharmacokinetics of a monoclonal antibody in rats.
AAPS PharmSci 4(4), 2002.
26. Hansen RJ and
Balthasar JP, Investigation of intravenous immunoglobulin
effects on anti-platelet antibody disposition in wild-type and
FcRn-deficient mice. AAPS PharmSci 4(4), 2002.
27. Lobo ED and Balthasar
JP, Utilization of anti-methotrexate Fab fragments to optimize
i.p. methotrexate (MTX) chemotherapy: Dose escalation and
enhancement of MTX efficacy in a mouse model of peritoneal
cancer. AAPS PharmSci 4(4), 2002.
28. Hansen RJ and
Balthasar JP, Quantitative analysis of the inhibitory effects of
intravenous immunoglobulin on anti-platelet antibody production,
in vitro. AAPS PharmSci 4(4), 2002.
29. Hansen RJ and
Balthasar JP, Application of PK/PD modeling for the
investigation of mechanisms of intravenous immunoglobulin action
in a rat model of immune thrombocytopenia. AAPS PharmSci
4(4), 2002.
30. Lobo ED and Balthasar
JP, Pharmacokinetic modeling of chemotherapeutic effects:
Application of a modified transduction model to characterize
methotrexate effects on two cancer cell lines, in vitro. AAPS
PharmSci 4(4), 2002.
31. Jin F and Balthasar
JP, Pharmacokinetic and pharmacodynamic effects of high-dose
monoclonal antibody therapy in a rat model of immune
thrombocytopenia. AAPS PharmSci 5(4), 2003.
32. Chen J and Balthasar
JP, Topotecan pharmacokinetics and toxicodynamics in mice.
AAPS PharmSci 5(4), 2003.
33. Deng R and Balthasar
JP, Investigation of antibody-coated liposomes in vivo and in
vitro as a therapy for immune thrombocytopenia. AAPS PharmSci
5(4), 2003.
34. Deng R and Balthasar
JP, Effects of antibody-coated liposome on 7E3-induced immune
thrombocytopenia (ITP) in rats. AAPS Journal 6(4),
2004.
35. Chen J and Balthasar
JP, The effects of endogenous anti-topotecan antibodies on
topotecan pharmacokinetics. AAPS Journal 6(4),
2004.
36. Jin F, Getman K and
Balthasar JP, Effects of a model FcRn inhibitor on the
disposition of monoclonal antibodies in rats. AAPS Journal
6(4), 2004.
37. Garg A and Balthasar
JP, Application of a physiologically-based pharmacokinetic (PBPK)
model to study the effects of FcRn and IVIG on IgG tissue
disposition. AAPS Journal 6(4), 2004.
38. Garg A and Balthasar
JP, Investigation of the Tissue Disposition of 7E3, a Murine
Monoclonal IgG1 Antibody, in Wild-Type and FcRn-Knockout Mice.
AAPS Journal 7(S2), 2005.
39. Deng R and Balthasar
JP, Pharmacokinetic/pharmacodynamic modeling of IVIG effects in
a murine model of immune thrombocytopenia. AAPS Journal 7(S2),
2005.
40. Jin F, Getman K and
Balthasar JP, Pharmacokinetic modeling of an anti-FcRn antibody
and its effect on IgG disposition in rats. AAPS Journal 7(S2),
2005.
41. Jin F and Balthasar
JP, Development and in vitro evaluation of antibodies directed
against the human neonatal Fc receptor (hFcRn). AAPS Journal
7(S2), 2005.
42. Urva S, Lu Q, and
Balthasar JP, Preclinical investigation of a new immune complex
therapy for treatment of immune thrombocytopenic purpura (ITP).
AAPS Journal 8(S2), 2006.
43. Garg A and Balthasar
JP, Application of a physiologically-based pharmacokinetic (PBPK)
model to predict IgG tissue kinetics in wild-type and FcRn-knockout
mice. AAPS Journal87(S2), 2006.
44. Garg A and Balthasar
JP, PBPK Analysis of the effects of IVIG and FcRn on IgG tissue
disposition. AAPS National Biotechnology Meeting, San Diego,
California, 2007.
45. Shah D, Chen Y, Shin BS, Chen J, Balthasar JP,
Simulations of the influence of antibody-ligand binding kinetics
on the pharmacokinetics of "high-clearance" ligands. Pfizer/UB
Alliance Annual Meeting, 2007
.
|
